Cardiff Oncology Inc (NASDAQ: CRDF) is a clinical-stage biotechnology company developing novel cancer therapies centered on PLK1 inhibition. The company has no product revenue, operating entirely on capital raises to fund clinical development of onvansertib, its oral, small-molecule PLK1 inhibitor. Onvansertib is being studied in combination with standard-of-care therapeutics across RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). The lead program is CRDF-004, a Phase 2 randomized multi-center trial in first-line RAS-mutated mCRC that enrolled 110 patients in the intent-to-treat population, conducted in partnership with Pfizer Ignite. Cardiff operates a biomarker laboratory in San Diego, California. Pfizer Inc. holds an equity stake acquired in November 2021 for gross proceeds of approximately $15.0 million under the Pfizer Breakthrough Growth Initiative. The company is pre-commercial with no disclosed product sales.

Revenue model

Cardiff Oncology generates no product revenue. The company funds operations through equity issuances, including a November 2021 securities purchase agreement with Pfizer Inc. for approximately $15.0 million in gross proceeds.

Products and services

Onvansertib: oral, small-molecule, highly selective PLK1 inhibitor with a 24-hour half-life. Active clinical programs include CRDF-004 (Phase 2, RAS-mutated mCRC, first-line, 110 patients enrolled), investigator-initiated Phase 2 trials in mPDAC, SCLC, mTNBC, and a Phase 1 dose-escalation trial in CMML. The company also operates an internal biomarker laboratory in San Diego, California.

Customers and end markets

No commercial customers as of the 10-K filed 2026-02-24. End markets are oncology patients with RAS-mutated mCRC, mPDAC, SCLC, mTNBC, and CMML. Clinical partners include Pfizer Ignite for the CRDF-004 trial.

Value-chain role

Drug developer and clinical-stage sponsor. Relies on third-party manufacturers for drug supply and third-party vendors to conduct preclinical studies and clinical trials. Does not manufacture or commercialize products.

Geographic exposure

Clinical operations in the United States. Biomarker laboratory located in San Diego, California. CRDF-004 is a multi-center trial; no further geographic breakdown disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-02-24

Industry: Biological Products, (No Diagnostic Substances) Peers: Black Diamond Therapeutics Inc Bolt Biotherapeutics Inc Cyteir Therapeutics, Inc. Equillium Inc Genprex Inc Synlogic Inc Passage Bio Inc TCR2 THERAPEUTICS INC. SQZ Biotechnologies Co